Meeting
2020 Genitourinary Cancers Symposium
Expectations for overall survival in mRCC patients who were selected for upfront cytoreductive nephrectomy in the targeted therapy era.
Authors
E. Jason Abel
University of Wisconsin School of Medicine and Public Health, Madison, WI
E. Jason Abel , Jose A. Karam , Philippe E. Spiess , Jay D. Raman , Wade J. Sexton , Logan Zemp , Alyssa Bilotta , Dattatraya Patil , Glenn O. Allen , Kate V. Lauer , Daniel D. Shapiro , Surena F. Matin , Christopher G. Wood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 646)
Abstract #
646
Poster Bd #
E10
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
First Author: Joseph Miccio
Poster
2019 Genitourinary Cancers Symposium
Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC).
First Author: Aly-Khan A. Lalani
Poster
2017 Genitourinary Cancers Symposium
Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
First Author: Igor Stukalin
Poster
2017 Genitourinary Cancers Symposium
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy.
First Author: Dipesh Uprety